Italia markets closed

Dynavax Technologies Corporation (0IDA.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
16,36-0,65 (-3,81%)
Alla chiusura: 05:25PM BST
Schermo intero
Chiusura precedente17,01
Aperto16,71
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno16,22 - 16,71
Intervallo di 52 settimane16,22 - 16,71
Volume1.098
Media VolumeN/D
Capitalizzazione3,466M
Beta (5 anni mensile)1,29
Rapporto PE (ttm)0,22
EPS (ttm)0,75
Prossima data utili02 nov 2022 - 07 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Clover’s COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous Booster

    SCB-2019 (CpG 1018/Alum) as a third dose exhibited a 19-fold boost in neutralizing antibodies against Omicron BA.2 variant among baseline seronegative participantsNew positive data adds to growing body of evidence supporting potential use of SCB-2019 (CpG 1018/Alum) as a universal COVID-19 booster vaccine SHANGHAI, China, June 27, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic th

  • GlobeNewswire

    Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines

    -- Study to evaluate SCB-2019 (CpG 1018/Alum) as a heterologous booster in individuals previously vaccinated with CoronaVac™ (Sinovac Inactivated Vaccine), Comirnaty® (Pfizer mRNA Vaccine), and Vaxzevria® (AstraZeneca Viral Vector Vaccine) -- -- Safety & immunogenicity data expected for key 3rd dose booster groups (CoronaVac™ and Comirnaty®) in Q3-2022 and the 4th dose booster group (CoronaVac™) in Q4-2022 -- -- Study to expand dataset supporting the potential use of SCB-2019 (CpG 1018/Alum) as

  • GlobeNewswire

    Clover Provides Update on 2022 Corporate Milestones

    -- Changxing manufacturing facility readiness and CMC activities impacted by COVID-19 outbreak in China - the facility is now expected to be ready for GMP inspections in Q3-2022 -- -- Regulatory submissions to the China NMPA, EMA, and the WHO for SCB-2019 (CpG 1018/Alum) are anticipated to be completed in the second half of 2022 -- -- Universal Booster Development: Phase 3 clinical trial evaluating SCB-2019 (CpG 1018/Alum) as a heterologous booster for CoronaVac™ and Comirnaty® expected to initi